Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (46987) 46987
Publication (4019) 4019
Newsletter (3039) 3039
Book Review (773) 773
Book Chapter (273) 273
Conference Proceeding (74) 74
Dissertation (74) 74
Magazine Article (35) 35
Book / eBook (34) 34
Newspaper Article (20) 20
Reference (10) 10
Trade Publication Article (9) 9
Data Set (6) 6
Web Resource (5) 5
Paper (4) 4
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (22483) 22483
humans (21176) 21176
male (18444) 18444
index medicus (14862) 14862
rats (13346) 13346
angiotensin (12913) 12913
female (9942) 9942
hypertension (9917) 9917
pharmacology & pharmacy (7017) 7017
angiotensin ii (6940) 6940
angiotensin-converting enzyme inhibitors - therapeutic use (6392) 6392
angiotensin-ii (6389) 6389
blood pressure - drug effects (5977) 5977
peripheral vascular disease (5737) 5737
angiotensin ii - pharmacology (5693) 5693
angiotensin receptor antagonists (5687) 5687
middle aged (5539) 5539
hypertension - drug therapy (5471) 5471
cardiac & cardiovascular systems (5303) 5303
renin-angiotensin system (5003) 5003
aged (4726) 4726
blood-pressure (4574) 4574
physiology (4322) 4322
rats, sprague-dawley (4301) 4301
research (4280) 4280
losartan (3937) 3937
blood pressure (3924) 3924
antihypertensive agents - therapeutic use (3844) 3844
mice (3837) 3837
adult (3669) 3669
renin-angiotensin system - drug effects (3381) 3381
heart failure (3297) 3297
hypertension - physiopathology (3270) 3270
expression (3261) 3261
angiotensin-converting enzyme inhibitors - pharmacology (3239) 3239
urology & nephrology (3100) 3100
angiotensin ii - metabolism (3026) 3026
dose-response relationship, drug (2995) 2995
cells, cultured (2938) 2938
tetrazoles - pharmacology (2916) 2916
rats, wistar (2840) 2840
treatment outcome (2775) 2775
risk factors (2736) 2736
oxidative stress (2671) 2671
antihypertensive agents - pharmacology (2670) 2670
physiological aspects (2606) 2606
analysis (2595) 2595
biochemistry & molecular biology (2503) 2503
renin-angiotensin system - physiology (2497) 2497
endocrinology & metabolism (2483) 2483
angiotensin ii type 1 receptor blockers - therapeutic use (2431) 2431
heart failure - drug therapy (2425) 2425
mortality (2414) 2414
imidazoles - pharmacology (2389) 2389
drug therapy, combination (2276) 2276
time factors (2255) 2255
receptor (2246) 2246
adrenergic beta-antagonists - therapeutic use (2241) 2241
angiotensin ii type 1 receptor blockers - pharmacology (2212) 2212
disease models, animal (2207) 2207
enzymes (2171) 2171
losartan - pharmacology (2133) 2133
medicine & public health (2129) 2129
diabetes (2099) 2099
angiotensin-converting enzyme (2077) 2077
receptors (2066) 2066
drug therapy (2033) 2033
renin (2032) 2032
system (2031) 2031
heart-failure (1997) 1997
aldosterone (1987) 1987
cell biology (1949) 1949
neurosciences (1933) 1933
angiotensin ii - antagonists & inhibitors (1932) 1932
inhibition (1906) 1906
angiotensin receptor antagonists - therapeutic use (1900) 1900
tetrazoles - therapeutic use (1883) 1883
activation (1880) 1880
ace inhibitors (1847) 1847
in vitro techniques (1843) 1843
receptors, angiotensin - metabolism (1840) 1840
care and treatment (1812) 1812
article (1809) 1809
medicine, general & internal (1794) 1794
health aspects (1772) 1772
nitric oxide (1769) 1769
nitric-oxide (1745) 1745
receptor, angiotensin, type 1 (1731) 1731
angiotensin ii - physiology (1728) 1728
rat (1725) 1725
myocardial-infarction (1721) 1721
inflammation (1706) 1706
signal transduction (1700) 1700
fibrosis (1675) 1675
cardiology (1642) 1642
heart (1635) 1635
medicine, research & experimental (1631) 1631
rodents (1607) 1607
medicine (1603) 1603
kidney (1587) 1587
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (48559) 48559
Japanese (390) 390
German (375) 375
French (218) 218
Russian (179) 179
Spanish (165) 165
Chinese (119) 119
Italian (71) 71
Portuguese (52) 52
Polish (44) 44
Korean (39) 39
Hungarian (33) 33
Danish (27) 27
Czech (19) 19
Swedish (15) 15
Dutch (14) 14
Norwegian (11) 11
Turkish (11) 11
Ukrainian (11) 11
Finnish (7) 7
Croatian (4) 4
Hebrew (4) 4
Lithuanian (3) 3
Slovak (3) 3
Slovenian (3) 3
Persian (2) 2
Romanian (2) 2
Serbian (2) 2
Bosnian (1) 1
Bulgarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Angiotensin II receptor antagonists
: current perspectives
by Mancia, Giuseppe
2006, 2nd ed., ISBN 1841845795, xii, 218
Saralasin | Angiotensins | Vasoconstrictors
Book
Details down arrow
2. Angiotensin II receptor antagonists in perspective
by Mancia, Giuseppe
2000, ISBN 1853179809, x, 175
Hypertension | Angiotensins | Receptors
Book
Details down arrow
3. Full Text Pregnancy Outcome Following Exposure to Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists: A Systematic Review
by Bullo, Marina and Tschumi, Sibylle and Bucher, Barbara S and Bianchetti, Mario G and Simonetti, Giacomo D
Hypertension, ISSN 0194-911X, 08/2012, Volume 60, Issue 2, pp. 444 - 450
The objective was to analyze the outcome following prenatal exposure to angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor antagonists... 
angiotensin-converting enzyme inhibitors | prenatal exposure | angiotensin receptor blockers | systematic review | fetopathy | pregnancy | MANAGEMENT | FETAL RENAL-FAILURE | SEVERE HYPERTENSION | TOXICITY | OLIGOHYDRAMNIOS | CAPTOPRIL | ACE-INHIBITORS | NEONATAL ANURIA | PERIPHERAL VASCULAR DISEASE | MATERNAL EXPOSURE | Prenatal Exposure Delayed Effects - epidemiology | Humans | Hypertension - drug therapy | Oligohydramnios - epidemiology | Renal Insufficiency - epidemiology | Incidence | Pregnancy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Angiotensin Receptor Antagonists - therapeutic use | Infant, Newborn | Pregnancy Outcome | Angiotensin Receptor Antagonists - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text OPINION Chemokine receptor antagonists: overcoming developmental hurdles
by Horuk, R
NATURE REVIEWS DRUG DISCOVERY, ISSN 1474-1776, 01/2009, Volume 8, Issue 1, pp. 23 - 33
Chemokine receptors have a key role in the pathogenesis of auto immune diseases, inflammation and viral infection. However, with the exception of selective... 
RHEUMATOID-ARTHRITIS | DUAL ANGIOTENSIN-II | MULTIPLE-SCLEROSIS | SMALL-MOLECULE | CC-CHEMOKINE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS | PHARMACOLOGY & PHARMACY | PERIPHERAL-BLOOD | MONOCYTE CHEMOTACTIC PROTEIN-1 | T-CELLS | AUTOIMMUNE ENCEPHALOMYELITIS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
by Ferrario, Carlos M and Schiffrin, Ernesto L
Circulation Research, ISSN 0009-7330, 01/2015, Volume 116, Issue 1, pp. 206 - 213
Aldosterone exerts its best known sodium homeostasis actions by controlling sodium excretion at the level of the distal tubules via activation of the apical... 
kidney failure, chronic | heart failure | hypertension | OXIDATIVE STRESS | CARDIAC & CARDIOVASCULAR SYSTEMS | SPONTANEOUSLY HYPERTENSIVE-RATS | HEART-FAILURE | BETA-HYDROXYSTEROID DEHYDROGENASE | PRESERVED EJECTION FRACTION | SELECTIVE ALDOSTERONE BLOCKER | ARTERIAL-HYPERTENSION | PERIPHERAL VASCULAR DISEASE | SMOOTH-MUSCLE-CELLS | ANGIOTENSIN-II RECEPTORS | HEMATOLOGY | ELEVATION MYOCARDIAL-INFARCTION | Animals | Cardiovascular Diseases - metabolism | Aldosterone - biosynthesis | Receptors, Mineralocorticoid - metabolism | Cardiovascular Diseases - drug therapy | Homeostasis - physiology | Humans | Mineralocorticoid Receptor Antagonists - pharmacology | Homeostasis - drug effects | Mineralocorticoid Receptor Antagonists - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists
by Michel, Martin C and Foster, Carolyn and Brunner, Hans R and Liu, Lisheng
Pharmacological Reviews, ISSN 0031-6997, 2013, Volume 65, Issue 2, pp. 809 - 848
Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection... 
ANION TRANSPORTING POLYPEPTIDE | ACTIVE METABOLITE E-3174 | HEALTHY MALE-VOLUNTEERS | SPONTANEOUSLY HYPERTENSIVE-RATS | PHARMACOLOGY & PHARMACY | HUMAN LIVER-MICROSOMES | PLASMA-PROTEIN BINDING | ISCHEMIC BRAIN-DAMAGE | THROMBOXANE A-INDUCED VASOCONSTRICTION | VASCULAR SMOOTH-MUSCLE | STAGE RENAL-DISEASE | Angiotensin II Type 1 Receptor Blockers - chemistry | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Diabetic Nephropathies - metabolism | Humans | Hypertension - drug therapy | Heart Failure - metabolism | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Heart Failure - drug therapy | Hypertension - metabolism | Tissue Distribution | Animals | Drug Interactions | Receptor, Angiotensin, Type 1 - metabolism | Molecular Structure | Binding Sites | Diabetic Nephropathies - prevention & control
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
by Barrera-Chimal, Jonatan and Girerd, Sophie and Jaisser, Frederic
Kidney International, ISSN 0085-2538, 08/2019, Volume 96, Issue 2, pp. 302 - 319
Chronic kidney disease (CKD) represents a global health concern, and its prevalence is increasing. The ultimate therapeutic option for CKD is kidney... 
clinical study | fibrosis | kidney injury | inflammation | aldosterone | ENDOTHELIN-B RECEPTOR | OXIDATIVE STRESS | ACTIVATED PROTEIN-KINASE | HEART-FAILURE | COLLAGEN GENE-EXPRESSION | ANGIOTENSIN-ALDOSTERONE SYSTEM | DIABETIC-NEPHROPATHY | GELATINASE-ASSOCIATED LIPOCALIN | SODIUM ZIRCONIUM CYCLOSILICATE | UROLOGY & NEPHROLOGY | RENAL INTERSTITIAL FIBROSIS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice
by Zannad, Faiez and Stough, Wendy Gattis and Rossignol, Patrick and Bauersachs, Johann and McMurray, John J. V and Swedberg, Karl and Struthers, Allan D and Voors, Aiaan A and Ruilope, Luis M and Bakris, George L and O'Connor, Christopher M and Gheorghiade, Mihai and Mentz, Robert J and Cohen-Solal, Alain and Maggioni, Aldo P and Beygui, Farzin and Filippatos, Gerasimos S and Massy, Ziad A and Pathak, Atul and Pina, Ileana L and Sabbah, Hani N and Sica, Domenic A and Tavazzi, Luigi and Pitt, Bertram and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
European Heart Journal, ISSN 0195-668X, 11/2012, Volume 33, Issue 22, pp. 2782 - U18
Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HFREF), and... 
Heart failure | Aldosterone antagonist spironolactone | Mineralocorticoid receptors | SERUM POTASSIUM LEVELS | CARDIAC & CARDIOVASCULAR SYSTEMS | POSTMYOCARDIAL INFARCTION | ANGIOTENSIN-ALDOSTERONE SYSTEM | ENDOTHELIAL FUNCTION | ATRIAL-FIBRILLATION | LEFT-VENTRICULAR DYSFUNCTION | ACUTE MYOCARDIAL-INFARCTION | SUDDEN CARDIAC DEATH | CHRONIC KIDNEY-DISEASE | RANDOMIZED ALDACTONE EVALUATION | Endomyocardial Fibrosis - etiology | Evidence-Based Practice | Glycated Hemoglobin A - metabolism | Humans | Heart Failure - physiopathology | Hydrocortisone - metabolism | Arrhythmias, Cardiac - physiopathology | Dose-Response Relationship, Drug | Kidney Diseases - chemically induced | Mineralocorticoid Receptor Antagonists - pharmacology | Risk Factors | Kaplan-Meier Estimate | Rats | Stroke Volume - drug effects | Treatment Outcome | Arrhythmias, Cardiac - etiology | Ventricular Remodeling - physiology | Ventricular Dysfunction, Left - physiopathology | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Randomized Controlled Trials as Topic | Myocardial Infarction - complications | Animals | Ventricular Dysfunction, Left - drug therapy | Dogs | Hyperkalemia - chemically induced | Endomyocardial Fibrosis - physiopathology | Mice | Practice Guidelines as Topic | Klinisk medicin | Clinical Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives
by Sarafidis, PA and Memmos, E and Alexandrou, ME and Papagianni, A
CURRENT PHARMACEUTICAL DESIGN, ISSN 1381-6128, 2018, Volume 24, Issue 46, pp. 5528 - 5536
Background: The use of single RAS-blockade is currently the recommended first-line treatment for proteinuric diabetic or non-diabetic nephropathy, as these... 
CONTROLLED TRIAL | proteinuria | eplerenone | HEART-FAILURE | ANGIOTENSIN-ALDOSTERONE SYSTEM | Chronic kidney disease | DIABETIC-NEPHROPATHY | mineralocorticoid receptor antagonist | spironolactone | SODIUM ZIRCONIUM CYCLOSILICATE | BLOOD-PRESSURE | PREDIALYSIS PATIENTS | albuminuria | finerenone | CONVERTING-ENZYME-INHIBITOR | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | CHRONIC KIDNEY-DISEASE
Journal Article
Details down arrow
10. Full Text Therapeutic Potential of Vasopressin Receptor Antagonists
by Ali, Farhan and Guglin, Maya and Vaitkevicius, Peter and Ghali, Jalal K
Drugs, ISSN 0012-6667, 2007, Volume 67, Issue 6, pp. 847 - 858
Arginine vasopressin (AVP) is a neuropeptide hormone that plays an important role in circulatory and sodium homeostasis, and regulating serum osmolality.... 
Heart failure | Vasopressin 2 antagonists | Cirrhosis | Hyponatraemia | Tolvaptan | Vasopressin 1 antagonists | Conivaptan | Inappropriate antidiuretic hormone secretion | Lixivaptan | Research and development | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | ARGININE-VASOPRESSIN | LEFT-VENTRICULAR DYSFUNCTION | DIABETES-INSIPIDUS | RENIN-ANGIOTENSIN SYSTEM | DOUBLE-BLIND | PHARMACOLOGICAL PROFILE | PHARMACOLOGY & PHARMACY | RAT-HEART | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | CONGESTIVE-HEART-FAILURE | SERUM SODIUM CONCENTRATION | Liver Cirrhosis - drug therapy | Humans | Heart Failure - physiopathology | Pyrroles | Morpholines - pharmacology | Arginine Vasopressin - physiology | Spiro Compounds - therapeutic use | Benzazepines - pharmacology | Azepines - therapeutic use | Heart Failure - drug therapy | Inappropriate ADH Syndrome - drug therapy | Azepines - pharmacology | Animals | Benzamides - therapeutic use | Inappropriate ADH Syndrome - physiopathology | Benzazepines - therapeutic use | Hyponatremia - physiopathology | Hyponatremia - drug therapy | Receptors, Vasopressin - physiology | Benzamides - pharmacology | Liver Cirrhosis - physiopathology | Antidiuretic Hormone Receptor Antagonists | Morpholines - therapeutic use | Spiro Compounds - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The renal effects of mineralocorticoid receptor antagonists
by Bianchi, Stefano and Batini, Valentina and Bigazzi, Roberto
International Journal of Cardiology, ISSN 0167-5273, 2015, Volume 200, pp. 20 - 24
Abstract Beyond its well known classic effects on renal water and electrolytes metabolism, an increasing amount of experimental and clinical evidence suggests... 
Cardiovascular | Hyperkalemia | Chronic kidney disease | Mineralocorticoid receptor antagonists | Glomerular filtration rate | Proteinuria | OXIDATIVE STRESS | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | HEART-FAILURE | PRIMARY ALDOSTERONISM | SPIRONOLACTONE | DOUBLE-BLIND | DYSFUNCTION | CHRONIC KIDNEY-DISEASE | EPLERENONE | Kidney - drug effects | Humans | Kidney Diseases - chemically induced | Mineralocorticoid Receptor Antagonists - pharmacology | Kidney Diseases - drug therapy | Mineralocorticoid Receptor Antagonists - adverse effects | Renin-Angiotensin System - drug effects | Kidney Diseases - metabolism | Physiological aspects | Corticosteroids | Analysis | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: Preclinical and clinical studies
by Smith, Maree T and Anand, Praveen and Rice, Andrew S. C
Pain, ISSN 0304-3959, 02/2016, Volume 157, Issue 2, pp. S33 - S41
Neuropathic pain affects up to 10% of the general population, but drug treatments recommended for the treatment of neuropathic pain are associated with modest... 
EMA200 | Postherpetic neuralgia | EMA300 | Angiotensin II type 2 receptor | EMA401 | Small molecule AT | Target validation | Peripheral neuropathic pain | Rodent neuropathic pain models | AT | Dorsal root ganglia | receptor knockout mice | Clinical mechanism of action | Clinical trial | Angiotensin II | receptor antagonist | Human DRG neurons | SYSTEM | RAT MODEL | CLINICAL NEUROLOGY | NEURITE OUTGROWTH | NG108-15 CELLS | ANESTHESIOLOGY | ANALGESIC EFFICACY | TRIALS | AT receptor knockout mice | AT RECEPTOR | PROTEIN-KINASE | INDUCED BONE PAIN | NEUROSCIENCES | Small molecule AT receptor antagonist | Animals | Double-Blind Method | Humans | Drug Evaluation, Preclinical | Angiotensin II Type 2 Receptor Blockers - therapeutic use | Neuralgia - drug therapy | Randomized Controlled Trials as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights